Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients

BackgroundHeterozygous familial hypercholesterolemia (HFH) is an autosomal dominant genetic disorder leading to a lifetime exposure to high low-density lipoprotein cholesterol (LDL-c) level and an increased risk of premature atherosclerotic cardiovascular disease (ASCVD). We evaluate the effect of a...

Full description

Bibliographic Details
Published in:	Frontiers in Cardiovascular Medicine
Main Authors:	Anthony Matta, Jean Pierre Rabès, Dorota Taraszkiewicz, Didier Carrié, Jérôme Roncalli, Jean Ferrières
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Subjects:	heterozygous familial hypercholesterolemia genetic variant cardiovascular disease LDL-c atherosclerosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2023.1182554/full

Similar Items

Association of high lipoprotein (a) level with carotid atherosclerosis and all-cause mortality
by: Anthony Matta, et al.
Published: (2025-09-01)

Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
by: Kasper Aalbæk Kjærgaard, et al.
Published: (2022-07-01)

ASSOTIATION OF THE GENETIC POLYMORPHISM E670G OF THE PCSK-9 AND THE SEVERITY OF THE CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN UZBEK POPULATION
by: R. B. Alieva, et al.
Published: (2019-09-01)

Asymptomatic Intracranial Artery Stenosis/Occlusion in Heterozygous Familial Hypercholesterolemia: Its Frequency and Implications for Cerebrovascular and Cardiovascular Events
by: Sayaka Funabashi, et al.
Published: (2024-08-01)

Activation of receptor-independent fluid-phase pinocytosis promotes foamy monocyte formation in atherosclerotic mice
by: WonMo Ahn, et al.
Published: (2024-12-01)

Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries
by: Marcello Arca, et al.
Published: (2023-11-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Vascular Dysfunction in Short-Term Hypercholesterolemia despite the Absence of Atherosclerotic Lesions
by: Alireza Garjani, et al.
Published: (2011-08-01)

Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers
by: Andrea Piccioni, et al.
Published: (2023-04-01)

Phenotype of heterozygous familial hypercholesterolemia caused by deletion of <i>LDLR</i> gene exons 2-10: a case report
by: A. M. Moiseeva, et al.
Published: (2024-12-01)

Effectiveness of fixed-dose combination of rosuvastatin and ezetimibe in heterozygous familial hypercholesterolemia from the RENAISSANCE registry
by: I. A. Alekseeva, et al.
Published: (2025-08-01)

Oral <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i> Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia
by: Maria Cristina Curia, et al.
Published: (2022-08-01)

Current causes of death in familial hypercholesterolemia
by: Victoria Marco-Benedí, et al.
Published: (2022-08-01)

Lipoprotein (a) levels in children with heterozygous familial hypercholesterolemia
by: Liliya F. Galimova, et al.
Published: (2024-12-01)

Life Course Approach for Managing Familial Hypercholesterolemia
by: Samuel S. Gidding, et al.
Published: (2025-04-01)

CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis
by: M. Doortje Reijman, et al.
Published: (2024-03-01)

Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial Hypercholesterolemia
by: Youmna Ghaleb, et al.
Published: (2022-03-01)

Echocardiographic Calcium Score of Aortic Valve Correlates with Coronary Artery Calcium Score in Heterozygous Familial Hypercholesterolemia
by: Angelo Baldassare Cefalù, et al.
Published: (2025-03-01)

Aorta of young and middle-aged heterozygous familial hypercholesterolemia patients shows no functional or morphological impairment assessed by MRI
by: Sami Soljanlahti, et al.
Published: (2008-08-01)

EFFECT OF PRUNE Prunus domestica CONSUMPTION ON BLOOD LIPID PROFILE IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA
by: Dorota Walkowiak-Tomczak, et al.
Published: (2018-12-01)

Expression of pro- and anti-inflammatory cytokines during anti-proprotein convertase subtilisin/kexin type 9 therapy in patients with statin-resistant familial hypercholesterolemia
by: Julieta Danira Morales-Portano, et al.
Published: (2024-07-01)

Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels
by: Sayaka Funabashi, et al.
Published: (2022-08-01)

Impact of changes in Achilles tendon thickening on cardiovascular events in patients with familial hypercholesterolemia
by: Hayato Tada, et al.
Published: (2024-06-01)

Adherence to the Healthy Nordic Food Index is associated with reduced plasma levels of inflammatory markers in patients with heterozygous familial hypercholesterolemia
by: Eirin B. Løvheim, et al.
Published: (2024-12-01)

Safety and Effectiveness of Low‐Density Lipoprotein Cholesterol–Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real‐World, Postmarketing, Single‐Arm Study
by: Koutaro Yokote, et al.
Published: (2024-11-01)

A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
by: Rai Ajit K. Srivastava
Published: (2023-06-01)

Inclisiran: A New Pharmacological Approach for Hypercholesterolemia
by: Stefania Angela Di Fusco, et al.
Published: (2022-11-01)

Familial hypercholesterolemia: current status of the problem, treatment, and prevention
by: S. A. Bliznyuk, et al.
Published: (2020-11-01)

Familial Hypercholesterolemia: From Clinical Suspicion to Novel Treatments
by: Saeid Mirzai, et al.
Published: (2023-11-01)

Early Atherosclerosis in Children in Familial Hypercholesterolemia : A 2 Case Report
by: Narumon Densupsoontorn, et al.
Published: (2020-08-01)

ANALYSIS OF THE TRADITIONAL RISK FACTORS INFLUENCE ON DEVELOPMENT OF ISCHEMIC HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA
by: V. A. Korneva, et al.
Published: (2017-06-01)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
by: Chang-Wook Nam, et al.
Published: (2019-11-01)

Management of myocardial infarction with Nonobstructive Coronary Arteries (MINOCA): a subset of acute coronary syndrome patients
by: Anthony G. Matta, et al.
Published: (2021-09-01)

Hypercholesterolemia - non-pharmacological treatment, monotherapy or combination therapy. Review of the literature
by: Weronika Łowicka, et al.
Published: (2024-08-01)

Mutation Analysis of the LDL Receptor Gene in Indian Families with Familial Hypercholesterolemia
by: Suyamindra S Kulkarni
Published: (2011-09-01)

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
by: Kosmas CE, et al.
Published: (2022-07-01)

Efficacy of Evolocumab in Patients with Hypercholesterolemia
by: Xuan Jin, et al.
Published: (2020-12-01)

Glucose metabolism in heterozygous familial hypercholesterolemia with a founder effect and a high diabetes prevalence: a cross-sectional study
by: Ana María González-Lleó, et al.
Published: (2025-08-01)

Cerebrotendinous xanthomatosis: a literature review and case study
by: Anthony Matta, et al.
Published: (2024-12-01)

Modified Diagnostic Criteria Tools for Familial Hypercholesterolemia without the Requirement for Clinical Genetic Testing: Rationale and Design of the MOOCS Adaptive Clinical Trial
by: Satyanarayana Upadhyayula
Published: (2024-10-01)